Oman Diabetes Drugs Market Size (2024 - 2029)

The Oman Diabetes Drugs Market is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes and the need for effective management solutions. Despite the current lower prevalence of diabetes in Oman, the anticipated rise in the diabetic population highlights a growing demand for diabetic drugs. These medications are crucial for stabilizing blood glucose levels and managing diabetes-related health complications. The government's initiatives, such as participation in global health campaigns, further underscore the commitment to addressing diabetes as a significant healthcare challenge, contributing to the expansion of the market size.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Oman Diabetes Drugs Market Market Size

Market Size of Oman Diabetes Drugs Industry

Oman Diabetes Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 212.26 Million
Market Size (2029) USD 292.31 Million
CAGR (2024 - 2029) 6.61 %

Major Players

Oman Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Oman Diabetes Drugs Market Analysis

The Oman Diabetes Drugs Market size is estimated at USD 212.26 million in 2024, and is expected to reach USD 292.31 million by 2029, growing at a CAGR of 6.61% during the forecast period (2024-2029).

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. Although the current numbers show that the existence of diabetes is comparatively lesser in Oman, the growth rate of the diabetic population is projected to be higher in the country. 

According to Mordor Intelligence, the diabetic population in Oman is expected to reach 0.84 million by 2027. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country and is one of the leading causes of premature death, morbidity, and loss of economic growth.

Oman, Ministry of Health, recently participated in the virtual launch of the WHO Global Diabetes Compact, organized jointly by the World Health Organization and the government of Canada aimed at raising awareness level about diabetes as a global disease, in addition to expanding prevention and treatment as part of primary health care and universal health coverage.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Oman Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Oman Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.

Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Need A Different Region Or Segment?
Customize Now

Oman Diabetes Drugs Market Size Summary

The Oman Diabetes Drugs Market is poised for significant growth over the forecast period, driven by the increasing prevalence of diabetes and the rising demand for effective management solutions. Diabetes drugs, particularly oral anti-diabetic agents, play a crucial role in stabilizing blood glucose levels and are widely used in the treatment of type 2 diabetes. The market is characterized by a strong preference for oral medications due to their ease of use, cost-effectiveness, and favorable safety profiles. Metformin, a key medication in this category, is expected to maintain its dominance in the market, supported by its extensive use and combination with other diabetes treatments. The government's initiatives, such as participation in global health campaigns and efforts to enhance awareness and access to diabetes care, further underscore the importance of managing this chronic condition in Oman.

The market landscape is consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca leading the charge. These companies are actively engaged in strategic mergers and acquisitions to expand their market presence and introduce new products. Recent developments, such as Novo Nordisk's clinical trials and partnerships in the UAE, highlight the dynamic nature of the market and the ongoing efforts to innovate and improve diabetes care. The Ministry of Health's commitment to equitable access to treatment and investment in diabetes education and prevention programs reflects a comprehensive approach to addressing the growing healthcare burden posed by diabetes in Oman. As the market continues to evolve, it is expected to benefit from advancements in drug development and a supportive regulatory environment.

Explore More

Oman Diabetes Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Insulins

      1. 2.1.1 Basal or Long Acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Biosimilar Insulins

        1. 2.1.4.1 Insulin Glargine Biosimilars

        2. 2.1.4.2 Human Insulin Biosimilars

    2. 2.2 Oral Anti-diabetic drugs

      1. 2.2.1 Biguanides

        1. 2.2.1.1 Metformin

      2. 2.2.2 Alpha-Glucosidase Inhibitors

        1. 2.2.2.1 Alpha-Glucosidase Inhibitors

      3. 2.2.3 Dopamine D2 receptor agonist

        1. 2.2.3.1 Bromocriptin

      4. 2.2.4 SGLT-2 inhibitors

        1. 2.2.4.1 Invokana (Canagliflozin)

        2. 2.2.4.2 Jardiance (Empagliflozin)

        3. 2.2.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.2.4.4 Suglat (Ipragliflozin)

      5. 2.2.5 DPP-4 inhibitors

        1. 2.2.5.1 Onglyza (Saxagliptin)

        2. 2.2.5.2 Tradjenta (Linagliptin)

        3. 2.2.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.2.5.4 Galvus (Vildagliptin)

      6. 2.2.6 Sulfonylureas

        1. 2.2.6.1 Sulfonylureas

      7. 2.2.7 Meglitinides

        1. 2.2.7.1 Meglitinides

    3. 2.3 Non-Insulin Injectable drugs

      1. 2.3.1 GLP-1 receptor agonists

        1. 2.3.1.1 Victoza (Liraglutide)

        2. 2.3.1.2 Byetta (Exenatide)

        3. 2.3.1.3 Bydureon (Exenatide)

        4. 2.3.1.4 Trulicity (Dulaglutide)

        5. 2.3.1.5 Lyxumia (Lixisenatide)

      2. 2.3.2 Amylin Analogue

        1. 2.3.2.1 Symlin (Pramlintide)

    4. 2.4 Combination drugs

      1. 2.4.1 Insulin combinations

        1. 2.4.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.4.2 Oral Combinations

        1. 2.4.2.1 Janumet (Sitagliptin and Metformin)

Oman Diabetes Drugs Market Size FAQs

The Oman Diabetes Drugs Market size is expected to reach USD 212.26 million in 2024 and grow at a CAGR of 6.61% to reach USD 292.31 million by 2029.

In 2024, the Oman Diabetes Drugs Market size is expected to reach USD 212.26 million.

Oman Diabetes Drugs Market Report Snapshots

OMAN DIABETES DRUGS MARKET Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)